

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Hanna, et al.

Group Art Unit: 1642

Appln. No.: 08/822,672

Examiner: Helm

Filed: April 2, 2001

Atty Dkt 37003/280062
C# M#

Title: COMBINED USE OF ANTI-CYTOKINE
ANTIBODIES AND ANTI-CD2 FOR THE
TREATMENT OF B CELL LYMPHOMA

RECEIVED
NOV 13 2002
TECH CENTER 1600/2900

November 7, 2002

* * * * *

INFORMATION DISCLOSURE STATEMENT

Attached is Form PTO-1449 listing the enclosed references for consideration by the Patent Office.

☒ This IDS is being filed more than 3 mos. after application filing date but before the first action on the merits, and the following paragraph will be included in this IDS:

Contingent Request Under Rule 97(c): Should a first action on the merits have been issued on the same day or before this Information Disclosure Statement is filed, please accept this Information Disclosure Statement under Rule 97(c) and charge the requisite Rule 17(p) fee to our Deposit Account No. 03-3975, under the above Atty Dkt. No., and proceed to consider this Information Disclosure Statement.

This IDS is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to comply fully.

Consideration of the foregoing and enclosures plus the return of a copy of the enclosed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 are earnestly solicited along with an early action on the merits.

Respectfully submitted,

Pillsbury Winthrop LLP

Robin L. Teskin, Reg. No 35,030

P.O. Box 10500
McLean, VA 22102
(703) 905-2000